Members; Officers. Within thirty (30) days after ----------------- the Effective Date, the Parties shall establish a Development Committee (the "Joint Development Committee"), and GSK and Adolor shall designate an equal --------------------------- number of representatives, up to a maximum total of eight (8) members on such Joint Development Committee. Each of GSK and Adolor may replace any or all of its representatives on the Joint Development Committee at any time upon written notice to the other Party. Such representatives shall include individuals who have clinical trial and regulatory experience and expertise in pharmaceutical drug development. A Party may designate a substitute to temporarily attend and perform the functions of such Party's designee at any meeting of the Joint Development Committee. GSK and Adolor each may, on advance written notice to the other Party, invite non-member representatives of such Party to attend meetings of the Joint Development Committee. The Joint Development Committee shall be chaired on an annual rotating basis by a representative of either Adolor or GSK, as applicable, with Adolor providing the first such chairperson. The chairperson shall appoint a secretary of the Joint Development Committee, who shall be a representative of the other Party and who shall serve for the same annual term as such chairperson.
Members; Officers. Within thirty (30) days after the Effective ----------------- Date, the Parties shall establish a joint steering committee (the "Joint ----- Steering Committee"), which shall consist of six (6) members, three (3) of whom ------------------ shall be designated by each of GSK and Adolor and shall have appropriate expertise, with at least two (2) members from each Party being at least at a vice president level. Each of GSK and Adolor may replace any or all of its representatives on the Joint Steering Committee at any time upon written notice to the other Party. A Party may designate a substitute to temporarily attend and perform the functions of such Party's designee at any meeting of the Joint Steering Committee. GSK and Adolor each may, on advance written notice to the other Party, invite non-member representatives of such Party to attend meetings of the Joint Steering Committee. The Joint Steering Committee shall be chaired on an annual rotating basis by a representative of either Adolor or GSK, as applicable, on the Joint Steering Committee, with Adolor providing the first such chairperson. The chairperson shall appoint a secretary of the Joint Steering Committee, who shall be a ** = Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. representative of the other Party and who shall serve for the same annual term as such chairperson.
Members; Officers. Within thirty (30) days after the Effective Date, the Parties shall establish a joint product committee (the "Joint Product Committee" or "JPC"), and MYLAN and THERAVANCE shall designate an equal number of representatives, up to a maximum total of eight (8) members on such JPC, with an equal number from each Party. Each of MYLAN and THERAVANCE may replace any or all of its representatives on the JPC at any time upon written notice to the other Party. Such representatives shall be employees of the Parties who have the relevant experience and expertise to complete the activities included in the Development Plan or Commercialization Plan (as the case may be) for the Licensed Product in the Field for the next twelve months. On an occasional basis a Party may designate a substitute employee to temporarily attend and perform the functions of such Party's JPC member at any meeting of the JPC. MYLAN and THERAVANCE each may invite non-member employees representatives of such Party to attend meetings of the JPC. The attendance of members of or any representatives to the JPC who are not employees of the applicable Party shall be subject to the prior written consent of the other Party, not to be unreasonably withheld, refused, conditioned or denied. From the Effective Date until the date that is thirty (30) days after the filing of the first NDA for the Licensed Product in the Field in the U.S. the JPC shall be chaired by a representative of THERAVANCE and MYLAN shall appoint a secretary of the JPC, who shall be a representative of MYLAN. Beginning thirty (30) days after filing of the first NDA for the Licensed Product in the Field in the U.S. the JPC shall be chaired by a representative of MYLAN and ***CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. THERAVANCE shall appoint a secretary of the JPC, who shall be a representative of THERAVANCE.
Members; Officers. Immediately after the Effective Date, the Parties shall establish a joint executive committee (the "Joint Executive Committee" or "JEC"), which shall consist of six members, three members from each of the Company and BMS. The initial members of the JEC are set forth on Exhibit 2.1. Each of the Company and BMS may replace any or all of its representatives on the JEC at any time upon written notice to the other in accordance with Section 16.5 of this Agreement. Such representatives shall at all times include each such Party's [**] and most senior pharmaceutical business officer and one other senior officer of each such Party. Any member of the JEC may designate a substitute to temporarily attend and perform the functions of that member at any meeting of the JEC. The Company and BMS each may, in its discretion, invite non-member representatives of such Party to attend meetings of the JEC. The JEC shall be co-chaired by a representative of each of the Company and BMS. The co-chairpersons shall appoint a secretary of the JEC, and such secretary shall serve for such term as designated by the co-chairpersons. The initial co-chairpersons and the initial secretary are designated on Exhibit 2.1.
Members; Officers. Immediately after the Effective Date, the Parties shall establish a product development committee (the "Product Development Committee" or "PDC"), which shall consist of an equal number of representatives from each of the Company and BMS, up to a maximum total of eight members on such Committee. Each of the Company and BMS may replace any or all of its representatives on the PDC at any time upon written notice to the other in accordance with Section 16.5 of this Agreement. Such representatives shall include individuals within the senior management of each such Party, and those representatives of each such Party shall, individually or collectively, have expertise in pharmaceutical drug development and/or marketing. Any member of the PDC may designate a substitute to temporarily attend and perform the functions of that member at any meeting of the PDC. The Company and BMS each may, in its discretion, invite non-member representatives of such Party to attend meetings of the PDC. The PDC shall be chaired by a representative of the Company. The secretary of the PDC shall be a representative of BMS.
Members; Officers. Immediately after the Effective Date, the Parties shall establish a joint commercialization committee (the "Joint Commercialization Committee" or "JCC"), which shall consist of an equal number of representatives from each of the Company and BMS, up to a maximum total of eight members on such Committee. Each of the Company and BMS may replace any or all of its representatives on the JCC at any time upon written notice to the other in accordance with Section 16.5 of this Agreement. Such representatives shall include individuals within the senior management of each such Party, and those representatives of each such Party shall, individually or collectively, have clinical experience and expertise in marketing and sales. Any member of the JCC may designate a substitute to temporarily attend and perform the functions of that member at any meeting of the JCC. The Company and BMS each may, in its discretion, invite non-member representatives of such Party to attend meetings of the JCC. The JCC shall be chaired by a representative of BMS. The secretary of the JCC shall be a representative of the Company.
Members; Officers. Immediately after the Effective Date, the Parties shall establish a joint manufacturing committee (the "Joint Manufacturing Committee" or "JMC"), which shall consist of an equal number of representatives from each of the Company and BMS, up to a maximum total of eight members on such Committee. Each of the Company and BMS may replace any or all of its representatives on the JMC at any time upon written notice to the other in accordance with Section 16.5 of this Agreement. Such representatives shall be comprised of members of senior management of each such Party with expertise in manufacturing. Any member of the JMC may designate a substitute to temporarily attend and perform the functions of that member at any meeting of the JMC. The Company and BMS each may, in its discretion, invite non-member representatives of such Party to attend meetings of the JMC. Except as provided in Section 8.12(f), the JMC shall be chaired by a representative of the Company. The secretary of the JMC shall be a representative of BMS.
Members; Officers. Within ten (10) days after each relevant Theravance Compound in a Discovery Program is accepted by GSK as an Alliance Product, the Parties shall establish a Program Committee for such Alliance Product (the "Joint Program Committee"), and GSK and Theravance shall designate an equal number of representatives, up to a maximum total of eight (8) members on such Joint Program Committee, with a maximum of four (4) from each Party. Each of GSK and Theravance may replace any or all of its representatives on the Joint Program Committee at any time upon written notice to the other Party. Such representatives shall include individuals who have the relevant experience and expertise for the next twelve months as included in the Development Plan for the relevant Alliance Product. A Party may designate a substitute to temporarily attend and perform the functions of such Party's designee at any meeting of the Joint Program Committee. GSK and Theravance each may, on advance written notice to the other Party, invite non-member representatives of such Party to attend meetings of the Joint Program Committee. The Joint Program Committee shall be chaired by a representative of GSK. The chairperson shall appoint a secretary of the Joint Program Committee, who shall be a representative of Theravance.
Members; Officers. The Parties hereby establish a joint development committee (the “Joint Development Committee” or “JDC”), which shall consist of up to [* * *] members with an equal number of members nominated by each of Durect and Alpharma, one of whom shall be designated by Alpharma as chairman. The initial representatives on the JDC are set forth on Schedule 2.2, as may be amended by the designating Party from time to time. Each of Durect and Alpharma may replace any or all of its representatives on the JDC at any time upon notice to the other Party. Such representatives shall be employees of each such Party or its Affiliates, and those representatives of each such Party shall, individually or collectively, have expertise in pharmaceutical drug development, regulatory matters, manufacturing, Clinical Trials, Non-Clinical studies and/or other expertise to the extent relevant. Any member of the JDC may designate a substitute with due authority to temporarily attend and perform the functions of that member at any meeting of the JDC. Durect and Alpharma each may invite non-member representatives that are employees of Alpharma or Durect (or their Affiliates) or external consultants of a Party to attend meetings of the JDC, provided that such external consultants have signed customary confidentiality agreements. The secretary of the JDC shall initially be designated by Alpharma and thereafter alternate between a representative of Durect and a representative of Alpharma.
Members; Officers. Within thirty (30) days after the Effective Date, the Parties shall establish a Project Committee (the "Joint Project Committee"), and GSK and Theravance shall designate an equal number of representatives, up to a maximum total of eight (8) members on such Joint Project Committee, with a maximum of four (4) from each Party. Each of GSK and Theravance may replace any or all of its representatives on the Joint Project Committee at any time upon written notice to the other Party. Such representatives shall include individuals who have the relevant experience and expertise for the next twelve months as included in the Development Plan for the Collaboration Products. A Party may designate a substitute to temporarily attend and perform the functions of such Party's designee at any meeting of the Joint Project Committee. GSK and Theravance each may, on advance written notice to the other Party, invite non-member representatives of such Party to attend meetings of the Joint Project Committee. The Joint Project Committee shall be chaired by a representative of GSK. The chairperson shall appoint a secretary of the Joint Project Committee, who shall be a representative of Theravance.
